Drug Delivery Implants in the Treatment of Vitreous Inflammation
The eye is a model organ for the local delivery of therapeutics. This proves beneficial when treating vitreous inflammation and other ophthalmic pathologies. The chronicity of certain diseases, however, limits the effectiveness of locally administered drugs. To maintain such treatments often require...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2013/780634 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849400611008675840 |
|---|---|
| author | Jillian Wang Angela Jiang Malav Joshi John Christoforidis |
| author_facet | Jillian Wang Angela Jiang Malav Joshi John Christoforidis |
| author_sort | Jillian Wang |
| collection | DOAJ |
| description | The eye is a model organ for the local delivery of therapeutics. This proves beneficial when treating vitreous inflammation and other ophthalmic pathologies. The chronicity of certain diseases, however, limits the effectiveness of locally administered drugs. To maintain such treatments often requires frequent office visits and can result in increased risk of infection and toxicity to the patient. This paper focuses on the implantable devices and particulate drug delivery systems that are currently being implemented and investigated to overcome these challenges. Implants currently on the market or undergoing clinical trials include those made of nonbiodegradable polymers, containing ganciclovir, fluocinolone acetonide, triamcinolone acetonide, and ranibizumab, and biodegradable polymers, containing dexamethasone, triamcinolone acetonide, and ranibizumab. Investigational intravitreal implants and particulate drug delivery systems, such as nanoparticles, microparticles, and liposomes, are also explored in this review article. |
| format | Article |
| id | doaj-art-8e3f9385d3ab43ee8b7108a0ee747e56 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-8e3f9385d3ab43ee8b7108a0ee747e562025-08-20T03:37:57ZengWileyMediators of Inflammation0962-93511466-18612013-01-01201310.1155/2013/780634780634Drug Delivery Implants in the Treatment of Vitreous InflammationJillian Wang0Angela Jiang1Malav Joshi2John Christoforidis3Department of Ophthalmology, The Ohio State University Wexner Medical Center, 915 Olentangy River Road, Suite 5000, Columbus, OH 43212, USADepartment of Ophthalmology, The Ohio State University Wexner Medical Center, 915 Olentangy River Road, Suite 5000, Columbus, OH 43212, USADepartment of Ophthalmology & Visual Science, The University of Arizona Medical Center, 655 N. Alvernon Way, Suite 108, Tucson, AZ 85711, USADepartment of Ophthalmology & Visual Science, The University of Arizona Medical Center, 655 N. Alvernon Way, Suite 108, Tucson, AZ 85711, USAThe eye is a model organ for the local delivery of therapeutics. This proves beneficial when treating vitreous inflammation and other ophthalmic pathologies. The chronicity of certain diseases, however, limits the effectiveness of locally administered drugs. To maintain such treatments often requires frequent office visits and can result in increased risk of infection and toxicity to the patient. This paper focuses on the implantable devices and particulate drug delivery systems that are currently being implemented and investigated to overcome these challenges. Implants currently on the market or undergoing clinical trials include those made of nonbiodegradable polymers, containing ganciclovir, fluocinolone acetonide, triamcinolone acetonide, and ranibizumab, and biodegradable polymers, containing dexamethasone, triamcinolone acetonide, and ranibizumab. Investigational intravitreal implants and particulate drug delivery systems, such as nanoparticles, microparticles, and liposomes, are also explored in this review article.http://dx.doi.org/10.1155/2013/780634 |
| spellingShingle | Jillian Wang Angela Jiang Malav Joshi John Christoforidis Drug Delivery Implants in the Treatment of Vitreous Inflammation Mediators of Inflammation |
| title | Drug Delivery Implants in the Treatment of Vitreous Inflammation |
| title_full | Drug Delivery Implants in the Treatment of Vitreous Inflammation |
| title_fullStr | Drug Delivery Implants in the Treatment of Vitreous Inflammation |
| title_full_unstemmed | Drug Delivery Implants in the Treatment of Vitreous Inflammation |
| title_short | Drug Delivery Implants in the Treatment of Vitreous Inflammation |
| title_sort | drug delivery implants in the treatment of vitreous inflammation |
| url | http://dx.doi.org/10.1155/2013/780634 |
| work_keys_str_mv | AT jillianwang drugdeliveryimplantsinthetreatmentofvitreousinflammation AT angelajiang drugdeliveryimplantsinthetreatmentofvitreousinflammation AT malavjoshi drugdeliveryimplantsinthetreatmentofvitreousinflammation AT johnchristoforidis drugdeliveryimplantsinthetreatmentofvitreousinflammation |